SEC Stock Data Quick Answer Archer-Daniels-Midland Co reported Total Revenue of $80.27 billion for fiscal year 2025. Archer-Daniels-Midland Co Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $80.27B -6.2% 2024 $85.53B -8.9% 2023 $93.94B -7.5% 2022 $101.56B +19.1% 2021 $85.25B +32.5% 2020 $64.36B -0.5% 2019 $64.66B +0.5% 2018 $64.34B +5.8% 2017 $60.83B -2.4% 2016 … Read more
Quick Answer Archer-Daniels-Midland Co reported Total Revenue of $80.27 billion for fiscal year 2025. Archer-Daniels-Midland Co — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $80.27B-6.2% $85.53B-8.9% $93.94B-7.5% $101.56B+19.1% $85.25B+32.5% $64.36B-0.5% Net Income $1.08B-40.1% $1.80B-48.3% $3.48B-19.7% $4.34B+60.2% $2.71B+52.9% $1.77B+28.5% Diluted EPS $2.23-38.9% $3.65-43.2% $6.43-16.6% $7.71+61.0% $4.79+52.1% $3.15+29.1% Total Assets $52.39B-1.7% … Read more
Quick Answer ADIAL PHARMACEUTICALS, INC. reported Shares Outstanding of 1.11 million shares for fiscal year 2025. ADIAL PHARMACEUTICALS, INC. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 1.11M +329.2% 2024 258,826 -84.4% 2023 1.66M +55.8% 2022 1.07M -94.9% 2021 20.95M +45.5% 2020 14.39M +38.8% 2019 10.37M +51.1% 2018 6.86M +110.0% 2017 … Read more
Quick Answer ADIAL PHARMACEUTICALS, INC. reported Operating Income of -$7.80 million for fiscal year 2025. ADIAL PHARMACEUTICALS, INC. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$7.80M +5.9% 2024 -$8.28M -20.3% 2023 -$6.89M +36.6% 2022 -$10.86M +43.7% 2021 -$19.29M -76.5% 2020 -$10.93M -32.5% 2019 -$8.24M -18.0% 2018 -$6.99M -602.0% 2017 -$995.3K … Read more
Quick Answer ADIAL PHARMACEUTICALS, INC. reported R&D Expense of $2.62 million for fiscal year 2025. ADIAL PHARMACEUTICALS, INC. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $2.62M -18.9% 2024 $3.23M +154.9% 2023 $1.27M -35.0% 2022 $1.95M -76.8% 2021 $8.40M +43.4% 2020 $5.85M +47.6% 2019 $3.97M +976.3% 2018 $368.5K +102.3% 2017 $182.1K … Read more
Quick Answer ADIAL PHARMACEUTICALS, INC. reported Stockholders Equity of $5.28 million for fiscal year 2025. ADIAL PHARMACEUTICALS, INC. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $5.28M +29.7% 2024 $4.07M -0.4% 2023 $4.08M +24.6% 2022 $3.28M -6.6% 2021 $3.51M -12.0% 2020 $3.99M -44.2% 2019 $7.14M +60.8% 2018 $4.44M +545.2% 2017 -$997.6K … Read more
Quick Answer ADIAL PHARMACEUTICALS, INC. reported Cash and Equivalents of $5.88 million for fiscal year 2025. ADIAL PHARMACEUTICALS, INC. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $5.88M +56.8% 2024 $3.75M +32.7% 2023 $2.83M -29.4% 2022 $4.00M -34.0% 2021 $6.06M +37.7% 2020 $4.40M -35.1% 2019 $6.78M +75.2% 2018 $3.87M … Read more
Quick Answer ADIAL PHARMACEUTICALS, INC. reported Total Assets of $6.67 million for fiscal year 2025. ADIAL PHARMACEUTICALS, INC. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $6.67M +32.3% 2024 $5.04M +6.5% 2023 $4.74M -17.4% 2022 $5.73M -23.3% 2021 $7.47M +36.1% 2020 $5.49M -28.5% 2019 $7.68M +63.4% 2018 $4.70M +13503.0% 2017 $34.5K … Read more
Quick Answer ADIAL PHARMACEUTICALS, INC. reported Diluted EPS of $11.93 per share (loss) for fiscal year 2025. ADIAL PHARMACEUTICALS, INC. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$11.93 +82.5% 2024 -$68.01 -1789.2% 2023 -$3.60 +71.7% 2022 -$12.71 -1122.1% 2021 -$1.04 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ … Read more
Quick Answer ADIAL PHARMACEUTICALS, INC. reported Net Income of -$7.98 million for fiscal year 2025. ADIAL PHARMACEUTICALS, INC. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$7.98M +39.6% 2024 -$13.20M -157.6% 2023 -$5.12M +59.8% 2022 -$12.73M +34.5% 2021 -$19.42M -78.3% 2020 -$10.89M -26.8% 2019 -$8.59M +26.1% 2018 -$11.63M -920.8% 2017 -$1.14M … Read more